Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Thromb J ; 18: 24, 2020.
Article in English | MEDLINE | ID: mdl-33041672

ABSTRACT

BACKGROUND: Air travel thrombosis continues to be a controversial topic. Exposure to hypoxia and hypobaric conditions during air travel is assumed a risk factor. The aim of this study is to explore changes in parameters of coagulation, fibrinolysis and blood flow in a rat model of exposure to hypobaric conditions that imitate commercial and combat flights. METHODS: Sixty Sprague-Dawley male rats, aged 10 weeks, were divided into 5 groups according to the type and duration of exposure to hypobaric conditions. The exposure conditions were 609 m and 7620 m for 2 and 12 h duration. Blood count, thrombin- antithrombin complex, D-dimer, interleukin-1 and interleukin-6 were analyzed. All rats went through flight angiography MRI at day 13-post exposure. RESULTS: No effect of the various exposure conditions was observed on coagulation, fibrinolytic system, IL-1 or IL-6. MRI angiography showed blood flow reduction in lower limb to less than 30% in 50% of the rats. The reduction in blood flow was more pronounced in the left vessel than in the right vessel (p = 0.006, Wilcoxon signed rank test). The extent of occlusion differed across exposure groups in the right, but not the left vessel (p = 0.002, p = 0.150, respectively, Kruskal-Wallis test). However, these differences did not correlate with the exposure conditions. CONCLUSION: In the present rat model, no clear correlation between various hypobaric conditions and activation of coagulation was observed. The reduction in blood flow in the lower limb also occurred in the control group and was not related to the type of exposure.

2.
Nutrients ; 10(3)2018 Mar 12.
Article in English | MEDLINE | ID: mdl-29534506

ABSTRACT

Recent data indicate that artificial sweeteners (AS) may have deleterious effects on glucose metabolism. The purpose of this study was to compare the effects of AS and the effects of a high fructose diet (HFrD) on glucose metabolism and insulin resistance (IR) in Sprague-Dawley (SD) rats. SD rats were fed either regular chow, chow with saccharin (Sac) (0.1 mg/mL) placed in their water, or HFrD for seven weeks. Glucose, insulin, and triglycerides (Tg) levels were measured upon completion. A homeostatic model assessment (HOMA)-IR index was used to determine insulin resistance. The liver was stained to detect signs of a fatty liver. Hepatic mRNA expression of glucose metabolism regulation genes, Srepb-1c (sterol regulatory element binding protein) and ChREB (α & ß) (carbohydrate response element binding protein), as well as other glycolytic and lipogenic genes including glucose-6-phosphatase (G6pc), were considered IR markers. Both HFrD and Sac significantly increased fasting blood glucose levels compare to the control (140 ± 5 and 137 ± 6 vs. 118 ± 3 mg/dL, respectively, p < 0.05). However, only HFrD increased insulin secretion (0.99 ± 0.12 vs. 0.7 ± 0.1 and 0.6 ± 0.1 ug/L), Tg levels (420 ± 43 vs. 152 ± 20 and 127 ± 13 mg/dL), and the HOMA-IR index (3.4 ± 0.4 vs. 2.3 ± 0.36 and 2.13 ± 0.3) (HFrD vs. control and sac, p < 0.05). Fatty liver changes were only observed in HFrD fed rats. The expression of ChREB ß, Srepb-1c, and G6pc mRNA were only significantly elevated (between 2-10 times folds, p < 0.05) in HFrD fed rats. Sac may increase fasting blood glucose but has no effect on liver insulin resistance.


Subject(s)
Diet, Carbohydrate Loading/adverse effects , Fructose/adverse effects , Hyperglycemia/etiology , Liver/metabolism , Non-Nutritive Sweeteners/adverse effects , Saccharin/adverse effects , Animals , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/genetics , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism , Biomarkers/blood , Biomarkers/metabolism , Blood Glucose/analysis , Gene Expression Regulation , Hyperglycemia/blood , Hyperglycemia/metabolism , Hyperglycemia/pathology , Insulin/blood , Insulin/metabolism , Insulin Resistance , Insulin Secretion , Liver/enzymology , Liver/pathology , Male , Metabolic Syndrome/blood , Metabolic Syndrome/etiology , Metabolic Syndrome/metabolism , Metabolic Syndrome/pathology , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/metabolism , Non-alcoholic Fatty Liver Disease/pathology , Rats, Sprague-Dawley , Triglycerides/blood , Weight Gain
3.
J Am Soc Hypertens ; 8(4): 227-31, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24560177

ABSTRACT

The antihypertensive treatment in patients with metabolic syndrome is unclear. We therefore used a rat model of the metabolic syndrome and compared the effects of enalapril, an angiotensin-converting-enzyme inhibitor, with candoxatril, a neutral endopeptidase inhibitor that inhibits degradation of atrial natriuretic peptide and, in addition to lowering blood pressure, exerts metabolically beneficial activity. Ten male Sprague Dawley rats were fed regular rat chow for 5 weeks. Fifty male Sprague Dawley rats were fed a high-fructose diet for 3 weeks, followed by addition of enalapril, 10 mg/Kg/d, or candoxatril, 25, 50, or 100 mg/Kg/d, for 2 weeks. Systolic blood pressure, plasma triglyceride level, and insulin level were measured at baseline and after 3 weeks and 5 weeks. Three weeks of a high-fructose diet led to a significant increase in all metabolic parameters. Candoxatril and enalapril lowered systolic blood pressure significantly (candoxatril -10 ± 1 to -22 ± 1 mm Hg and enalapril -27 ± 2 mm Hg). High-dose candoxatril and enalapril significantly decreased plasma triglyceride levels (by 17.8% and 32.8%, respectively), but only high-dose candoxatril decreased plasma insulin levels significantly (by 25.3%). High-dose candoxatril is a metabolically favorable option for lowering blood pressure in a rat model of metabolic syndrome.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Antihypertensive Agents/pharmacology , Enalapril/pharmacology , Indans/pharmacology , Metabolic Syndrome/drug therapy , Propionates/pharmacology , Animals , Disease Models, Animal , Insulin/blood , Male , Rats , Rats, Sprague-Dawley , Triglycerides/blood
4.
Clin Transplant ; 27(4): 562-6, 2013.
Article in English | MEDLINE | ID: mdl-23758483

ABSTRACT

BACKGROUND: Kidney transplant patients are a unique population where despite correction of their kidney function they are still considered to be at high cardiovascular (CV) risk. Adiponectin, an adipokine secreted from adipocytes, has protective CV properties. Patients with essential hypertension (HTN) have low adiponectin levels that are associated with a high CV risk. The aim of this study was to assess adiponectin levels in hypertensive renal transplant recipients. MATERIALS AND METHODS: Fasting blood adiponectin levels were measured in hypertensive kidney transplant patients (n = 18), patients with essential HTN (n = 17) and healthy subjects (n = 14). Patients with diabetes mellitus and renal failure were excluded from the study. Anthropomorphic and metabolic parameters were also measured. RESULTS: Patients with essential HTN had lower adiponectin levels than healthy controls (6 ± 0.7 µg/mL vs. 11 ± 0.9 µg/mL, p < 0.001), whereas hypertensive kidney transplant patients had adiponectin levels that were similar to adiponectin levels found in normal controls (11 ± 1.1 µg/mL). Adiponectin levels in healthy subjects were inversely correlated with plasma triglycerides (r = -0.876, p < 0.001) and with body weight (r = -0.7, p < 0.001). There was no such a correlation in patients with HTN. CONCLUSION: Adiponectin in hypertensive kidney transplant recipients is not an appropriate CV risk marker as it does not adequately distinguish these patients from normal controls.


Subject(s)
Adiponectin/blood , Biomarkers/blood , Cardiovascular Diseases/diagnosis , Hypertension/diagnosis , Kidney Failure, Chronic/complications , Kidney Transplantation/adverse effects , Adolescent , Adult , Aged , Cardiovascular Diseases/blood , Cardiovascular Diseases/etiology , Case-Control Studies , Cross-Sectional Studies , Female , Follow-Up Studies , Glomerular Filtration Rate , Humans , Hypertension/blood , Hypertension/etiology , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/surgery , Kidney Function Tests , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Risk Factors , Young Adult
5.
Isr Med Assoc J ; 15(3): 170-3, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23662381

ABSTRACT

BACKGROUND: Allium sativum, the active ingredient in garlic, is known to have a beneficial effect on major cardiovascular risk factors, including dyslipidemia, blood pressure, blood glucose and insulin levels. However, the data on the significance of these effects are inconsistent due to methodological limitations, especially the use of whole garlic cloves which does not allow controlled dosing of the active compound. OBJECTIVES: To study the effects of purified allicin on the cardiovascular system. METHODS: Spontaneously hypertensive rats treated for 6 weeks with a daily dose of 80 mg/kg/day of purified allicin added to their chow were compared to control rats that were fed regular chow. Weight, systolic blood pressure (SBP), triglycerides, cholesterol, insulin and adiponectin were measured at baseline and at the end of the study. RESULTS: Allicin had no effect on body weight whereas it reduced SBP significantly from 190 +/- 7.5 mmHg to 168 +/- 5.7 (P < 0.0001) and triglyceride levels from 96 +/- 25 mg/dl to 71 +/- 19 (P = 0.009). Allicin had no effect on plasma cholesterol, insulin and adiponectin levels. CONCLUSIONS: Allicin lowered blood pressure and triglyceride levels in spontaneously hypertensive rats. This effect was not mediated through weight loss.


Subject(s)
Blood Pressure/drug effects , Hypertension , Sulfinic Acids , Triglycerides/blood , Adiponectin/blood , Administration, Oral , Animals , Antioxidants/administration & dosage , Antioxidants/adverse effects , Body Weight/drug effects , Cholesterol/blood , Disulfides , Dose-Response Relationship, Drug , Drug Monitoring , Hypertension/blood , Hypertension/drug therapy , Insulin/blood , Male , Rats , Rats, Inbred SHR , Sulfinic Acids/administration & dosage , Sulfinic Acids/adverse effects , Treatment Outcome
6.
Exp Eye Res ; 103: 33-40, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22960317

ABSTRACT

Form deprivation and low illuminance of ambient light are known to induce myopia in chicks. Low concentrations of retinal dopamine, a light-driven neurohormone, was previously shown to be associated with form deprivation myopia. In the present study we examined the dependence of retinal dopamine release in chicks on illuminance during light-dark cycles and in continuous light, and the role of retinal dopamine release in illuminance dependent refractive development. Newly hatched chicks (n = 166) were divided into two experimental groups, a dopamine (n = 88) and a refraction group (n = 78). Both groups were further divided into six illumination groups for exposure of chicks to illuminances of 50, 500 or 10,000 lux of incandescent illumination (referred to throughout as low, medium, and high illuminance, respectively), either under a light-dark cycle with lights on between 7 AM and 7 PM or under continuous illumination. For the dopamine experiment, chicks were euthanized and vitreous was extracted on day 14 post-hatching at 7, 8 AM and 1 PM. Vitreal dihydroxyphenylacetic acid (DOPAC) and dopamine concentrations were quantified by high-performance liquid chromatography coupled to electrochemical detection. For the refraction experiment, chicks underwent refraction, keratometry and A-scan ultrasonography on days 30, 60 and 90 post-hatching, and each of those measurements was correlated with vitreal DOPAC concentration measured at 1 PM (representing the index of retinal dopamine release). The results showed that under light-dark cycles, vitreal DOPAC concentration was strongly correlated with log illuminance, and was significantly correlated with the developing refraction, corneal radius of curvature, and axial length values. On day 90, low vitreal DOPAC concentrations were associated with myopia (-2.41 ± 1.23 D), flat cornea, deep anterior and vitreous chambers, and thin lens. Under continuous light, vitreal DOPAC concentrations measured at 1 PM in the low, medium, and high illuminance groups did not differ from the concentrations measured at 8 AM. On day 90, low DOPAC concentrations were associated with emmetropia (+0.63 ± 3.61), steep cornea, and shallow vitreous chamber. We concluded that ambient light over a log illuminance range of 1.69-4 is linearly related to vitreal DOPAC concentration. Under both light-dark cycles and continuous light, the intensity of ambient light regulates the release of retinal dopamine. Refractive development is associated with illuminance dependent dopamine release.


Subject(s)
Dopamine/metabolism , Light , Myopia/metabolism , Refraction, Ocular/physiology , Retina/radiation effects , 3,4-Dihydroxyphenylacetic Acid/metabolism , Animals , Animals, Newborn , Axial Length, Eye , Chickens , Chromatography, High Pressure Liquid , Circadian Rhythm/physiology , Corneal Pachymetry , Dark Adaptation , Female , Male , Microscopy, Acoustic , Myopia/physiopathology , Retina/metabolism , Vitreous Body/metabolism
7.
Am J Hypertens ; 25(5): 612-9, 2012 May.
Article in English | MEDLINE | ID: mdl-22258332

ABSTRACT

BACKGROUND: Premenopausal women have lower blood pressure (BP) levels than men of similar age. Adiponectin has been shown to play a role in the pathogenesis of hypertension. The aim of the present study was to compare the effect of various stress stimuli on BP and plasma adiponectin levels in male and female Sprague Dawley (SD) rats. METHODS: In three experimental models of hypertension, fructose-enriched diet, high salt diet, or L-NAME, were administered for up to 4 weeks. BP, metabolic parameters, and plasma adiponectin were measured at baseline and during the studies. The fructose diet protocol was repeated in female rats for 2 weeks with the addition of testosterone injections or vehicle. RESULTS: Females, in contrast to males, did not develop fructose-induced hypertension. Total plasma triglycerides (TGs) were half in females at baseline (P < 0.001) and a third at 4 weeks (P < 0.05). Plasma insulin levels were 23% lower in females than in males at baseline (P < 0.05) and 42% lower after 4 weeks of fructose-enriched diet (P = 0.001). Plasma adiponectin levels were 65% higher in females than in males at baseline (P = 0.001) and 45% higher after 4 weeks of fructose-enriched diet (P < 0.05). Furthermore, female rats showed blunted BP response and elevated plasma adiponectin in the salt-induced and L-NAME-induced hypertension models. Testosterone injection to female rats reduced plasma adiponectin and reversed the blunted BP response. CONCLUSIONS: Elevated plasma adiponectin levels, perhaps due to lack of suppression by testosterone, are associated with a blunting of BP response in female compared to male SD rats.


Subject(s)
Adiponectin/blood , Blood Pressure/drug effects , Fructose/pharmacology , Hypertension/physiopathology , NG-Nitroarginine Methyl Ester/pharmacology , Sodium Chloride, Dietary/pharmacology , Animals , Blood Pressure/physiology , Disease Models, Animal , Female , Fructose/adverse effects , Hypertension/blood , Hypertension/chemically induced , Male , NG-Nitroarginine Methyl Ester/adverse effects , Rats , Rats, Sprague-Dawley , Sex Characteristics , Sodium Chloride, Dietary/adverse effects , Stress, Physiological/physiology , Testosterone/pharmacology
8.
Am J Hypertens ; 25(2): 159-64, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22012209

ABSTRACT

BACKGROUND: The circadian pattern of blood pressure (BP) has yet to be defined among individuals with orthostatic hypotension (OH). The objective of this study was to evaluate whether OH is associated with nocturnal change in systolic BP. METHODS: In a prospective study, we evaluated patients who were referred for 24-h ambulatory blood pressure monitoring (ABPM). All subjects underwent orthostatic BP testing before recording their respective 24-h ABPM. RESULTS: The study includes 185 subjects, 114 males, mean age 58 ± 18 years (range 19-89). Participants were classified, based on pattern of systolic BP changes at night, as dippers (greater than 10% decrease; n = 74), nondippers (0-10% decrease; n = 77), and reverse-dippers (increase; n = 34). Nineteen patients (10.3%) had OH. Almost all participants with OH (95%) had an abnormal diurnal BP pattern, and most of them (58%) were reverse-dippers, whereas only 56% of the participants without OH had an abnormal diurnal BP variation, and only 14% were reverse-dippers (P < 0.001). Systolic BP decreased with upright posture by 12 and 2 mm Hg in the reverse-dippers and the nondippers, respectively, and increased by 2 mm Hg in the dippers (P < 0.001). Postural changes in systolic BP were inversely related to the changes between day and night BP readings(r = -0.43; P < 0.01). In a multivariate linear regression analysis, orthostatic BP change, use of ≥2 antihypertensive drugs and female sex were related to nocturnal BP changes. CONCLUSIONS: The decrease in BP during upright posture may be a marker of nondipping or reverse-dipping pattern of diurnal BP.


Subject(s)
Blood Pressure/physiology , Circadian Rhythm/physiology , Hypotension, Orthostatic/physiopathology , Adult , Aged , Aged, 80 and over , Antihypertensive Agents/adverse effects , Blood Pressure/drug effects , Blood Pressure Monitoring, Ambulatory , Circadian Rhythm/drug effects , Drug Therapy, Combination/adverse effects , Female , Humans , Hypotension, Orthostatic/chemically induced , Male , Middle Aged , Prospective Studies , Sex Factors , Young Adult
9.
Hypertens Res ; 34(11): 1233-8, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21796129

ABSTRACT

Measures derived from the slope of the linear relationship between systolic and diastolic pressures obtained by 24-h ambulatory blood pressure (ABP) measurements incorporate clinical and prognostic information, and are believed to be vascular markers. Using post hoc analysis, we investigated potential changes of these 'slope-related measures' in three different studies conducted in hypertensive patients with before and after 24-h ABP measurements, and also evaluated the sensitivity of the results to the analysis method. Two interventional studies included 8-week device-guided breathing (DGB) exercised by 13 patients with uncontrolled blood pressure (BP), and a 6-month mineral potassium chloride-enriched diet administered to 20 elderly patients. One study was observational and involved winter-to-summer change experienced by 13 patients with controlled BP. Slope-related measures included systolic-on-diastolic slope and its equivalent 1-(diastolic-on-systolic slope) called Ambulatory Arterial Stiffness Index, and were determined using three different BP-averaging methods and two types of regression procedures. Results demonstrated sensitivity of slope-related measures to the analysis method, the most significant changes were found when the before and after 24-h ABP profiles included hourly averaged BP further averaged over the patient population, and slope-related measures were determined using symmetric (and not standard) regression. DGB was found to reduce significantly all these measures. The changes in the slope-related variables for individual patients correlated negatively with its baseline value and positively with the observed pulse pressure changes. In conclusion, the study provides evidence that DGB can affect positively vascular markers associated with cardiovascular risk, and suggests improved analysis methods for the determination of slope-related measures in interventional studies.


Subject(s)
Arteries/physiology , Blood Pressure Monitoring, Ambulatory , Blood Pressure/physiology , Breathing Exercises , Hypertension/physiopathology , Potassium Chloride/administration & dosage , Seasons , Adult , Aged , Aged, 80 and over , Arteries/drug effects , Blood Pressure/drug effects , Diastole/drug effects , Diastole/physiology , Dietary Supplements , Female , Humans , Longitudinal Studies , Male , Middle Aged , Potassium Chloride/pharmacology , Regression Analysis , Retrospective Studies , Systole/drug effects , Systole/physiology , Vasodilation/drug effects , Vasodilation/physiology
10.
Basic Clin Pharmacol Toxicol ; 107(2): 663-8, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20210788

ABSTRACT

Rats given fructose-enriched diet develop many characteristics of the human metabolic syndrome and non-alcoholic fatty liver disease. In this study, we characterized the hepatic effects of rosiglitazone in fructose-enriched diet rats. Rats were randomly divided into three groups. One group was maintained on standard rat chow diet for 6 weeks, whereas the other two groups were given fructose-enriched diet for 6 weeks. Four weeks after the initiation of fructose-enriched diet, one of the fructose-enriched diet groups was also given rosiglitazone (10 mg/kg/day) for an additional 2 weeks. Rosiglitazone administration to the fructose-enriched diet rats was associated with decreases in the following parameters: blood pressure (-17%), plasma triglycerides (-62%), hepatic total lipids (-19%), hepatic triglycerides (-61%), hepatic malondialdehyde (-88%), glutathione reductase activity (-84%). An increase in adiponectin plasma levels (+329%), hepatic phospholipids (+46%), hepatic alpha-tocopherol concentrations (+24%) and hepatic paraoxonase activity (+68%) was observed. Rosiglitazone caused a decrease in hepatic macrovesicular steatosis score but no change in hepatic fibrosis. Administration of rosiglitazone, to rats with the metabolic syndrome has limited hepatic favourable effects: it improves hepatic lipid metabolism, decreases macrovesicular steatosis and improves some of the hepatic oxidative-anti-oxidative milieu but has no effect on hepatic fibrosis.


Subject(s)
Hypoglycemic Agents/pharmacology , Liver/drug effects , Metabolic Syndrome/drug therapy , Thiazolidinediones/pharmacology , Adiponectin/metabolism , Animal Feed , Animals , Aryldialkylphosphatase/metabolism , Blood Pressure/drug effects , Fatty Liver/chemically induced , Fatty Liver/drug therapy , Fatty Liver/metabolism , Fructose/administration & dosage , Glutathione Reductase/metabolism , Lipid Metabolism/drug effects , Lipids/analysis , Liver/metabolism , Liver Cirrhosis/chemically induced , Liver Cirrhosis/drug therapy , Liver Cirrhosis/metabolism , Male , Malondialdehyde/metabolism , Metabolic Syndrome/chemically induced , Phospholipids/metabolism , Rats , Rats, Sprague-Dawley , Rosiglitazone , alpha-Tocopherol/metabolism
11.
J Hypertens ; 28(1): 95-101, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19770680

ABSTRACT

BACKGROUND: High sodium intake is associated with increased risk of end-organ damage, independent of blood pressure (BP) levels. The protective peptide adiponectin may play a role in the pathogenesis of hypertension and particularly in salt-loaded conditions. Furthermore, increased adiponectin levels were observed in salt-loaded conditions. However, there is little information on the direct effect of high-salt diet on plasma adiponectin. The aim of the present study was to examine the effect of high-salt diet on adiponectin levels in Sprague-Dawley rats and explore the mechanisms that regulate adiponectin levels under salt loading. METHODS: Sprague-Dawley rats were fed either standard chow diet or medium or high sodium diet for 5 weeks. BP and plasma adiponectin were measured at baseline and during the study. In additional studies the same protocol was repeated with the addition of clonidine, telmisartan, hydralazine or eplerenone. RESULTS: High-salt diet increased systolic BP, suppressed plasma aldosterone levels and attenuated body weight gain. Five weeks of salt loading increased plasma adiponectin levels in a dose-dependent manner (medium salt and high salt were 47 and 93% higher than control, respectively, P < 0.05). Hydralazine and clonidine attenuated salt-induced BP increase but did not attenuate the increase in adiponectin levels whereas, telmisartan, an angiotensin receptor blocker, and eplerenone, an aldosterone blocker, attenuated both the increase in BP and in adiponectin levels. CONCLUSIONS: High salt intake increases adiponectin levels independent of the increase in BP. This effect is mediated through the renin-angiotensin-aldosterone system.


Subject(s)
Adiponectin/blood , Blood Pressure/physiology , Hypertension/blood , Renin-Angiotensin System/physiology , Sodium Chloride, Dietary/administration & dosage , Animals , Antihypertensive Agents/pharmacology , Benzimidazoles/pharmacology , Benzoates/pharmacology , Blood Pressure/drug effects , Clonidine/pharmacology , Eplerenone , Hydralazine/pharmacology , Hypertension/drug therapy , Male , Rats , Rats, Sprague-Dawley , Renin-Angiotensin System/drug effects , Spironolactone/analogs & derivatives , Spironolactone/pharmacology , Telmisartan
12.
Blood Press Monit ; 14(6): 239-44, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19918172

ABSTRACT

OBJECTIVE: Hypertension is unusual in young adults. Malingering hypertension is clinically suspected when there is a potential external secondary gain, absence of patient cooperation during diagnostic evaluation and a lack of response to antihypertensive treatment. The aim of this study was to investigate the possibility that abnormal ambulatory blood pressure patterns may be indicative of malingering hypertension rather than hypertension itself. METHODS: Young adults aged 19-20 years, referred for evaluation of high ambulatory blood pressure, underwent a detailed clinical interview, physical examination, and both in-clinic and 24-h ambulatory blood pressure monitoring. Blood pressure patterns were compared in patients with normal blood pressure values, essential hypertension, or suspected malingering hypertension (20 in each group). RESULTS: Both the suspected malingering hypertension and the essential hypertension group had higher blood pressure values during day and night than the normotensive group. Compared with essential hypertension subjects, the malingering hypertension group showed a greater fluctuation of blood pressure values, lower total percentage of time of abnormally high systolic blood pressure values during the day (41.9+/-16 vs. 65.9+/-12.4, P<0.001) and night (41.8+/-25 vs. 69+/-22.4, P=0.001), and higher maximum heart rate values during the day (132.8+/-15.2 vs. 115.1+/-11.6, P<0.001) and night (93.4+/-19.2 vs. 80.5+/-13.2, P=0.028). CONCLUSION: Patients with malingering hypertension form a distinct clinical group. We suggest that the diagnostician rely on clinical suspicion, fulfillment of our proposed criteria, and distinguishable characteristics of blood pressure patterns. Successful recognition of malingering hypertension can spare patients from unnecessary medical and surgical treatments.


Subject(s)
Blood Pressure Monitoring, Ambulatory , Hypertension/diagnosis , Malingering/diagnosis , Diagnosis, Differential , Female , Humans , Male , Patient Compliance , Young Adult
13.
Am J Hypertens ; 22(10): 1126-9, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19730415

ABSTRACT

BACKGROUND: Adiponectin is an important vascular protective adipocytokine that possesses antidiabetic, antiatherogenic, and anti-inflammatory properties. The aim of this study was to evaluate the effect of various antihypertensive drugs on the production and secretion of adiponectin from adipocytes. METHODS: 3T3-L1 adipocytes were incubated for 6 h with increased doses of the following drugs: hydrochlorothiazide, atenolol, losartan, telmisartan, captopril, and nifedipine. Adiponectin levels, as well as adiponectin-mRNA expression, were measured in the medium and cells. RESULTS: Significant increases of adiponectin were induced by telmisartan: 56% with a dose of 0.1 micromol/l (P < 0.05), 131% with 10 micromol/l (P < 0.05), and 125% with 100 micromol/l (P < 0.01). Losartan (100 micromol/l) also increased adiponectin by 65% (P < 0.05). Conversely, hydrochlorothiazide, 0.1 micromol/l, reduced adiponectin by 37% (P < 0.01). Captopril, atenolol, and nifedipine had no effect on adiponectin. Gene expression of adiponectin correlated with these results: with telmisartan, it increased by 27%, and with hydrochlorothiazide it decreased by 38% (P < 0.05 for both compared to the control). CONCLUSION: In this comparative model, telmisartan, and to a lesser extent, losartan, increased production and secretion of adiponectin from 3T3-L1 adipocytes compared to the other antihypertensive drugs.


Subject(s)
Adipocytes/metabolism , Adiponectin/metabolism , Antihypertensive Agents/pharmacology , 3T3-L1 Cells , Adipocytes/drug effects , Adiponectin/genetics , Animals , Atenolol/pharmacology , Benzimidazoles/pharmacology , Benzoates/pharmacology , Captopril/pharmacology , Hydrochlorothiazide/pharmacology , Losartan/pharmacology , Mice , Nifedipine/pharmacology , RNA, Messenger/metabolism , Telmisartan
14.
Am J Hypertens ; 21(9): 1018-22, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18566592

ABSTRACT

BACKGROUND: The etiology of the metabolic syndrome (MS) includes both genetic and environmental factors. The two most commonly studied animal models of the MS are the high-sucrose diet given to spontaneously hypertensive rats (SHRs) and high-fructose diet given to Sprague Dawley rats (SDRs). This study compares between these two models. METHODS: The two rat strains were examined; within each group, the rats were assigned to either the high-sugar diet (SDRs with fructose-enriched diet and SHRs with sucrose-enriched diet) or standard rat chow (control group). The rats were followed for 7 weeks. The main MS components (obesity, hypertension, impaired glucose tolerance, hyperinsulinemia, hypertriglyceridemia, and hypercholesterolemia) were measured. RESULTS: At baseline systolic blood pressure (SBP), fasting blood levels of triglycerides and insulin, as well as glucose intolerance, were significantly higher among the SHRs compared to SDRs. Following fructose enrichment, SDRs became hyperinsulinemic, hypertriglyceridemic, hypercholesterolemic, hypertensive, and insulin resistant, whereas SHRs responded to sucrose supplementation by a significant elevation in blood pressure and mild worsening of insulin resistance. Endpoint results revealed superiority of sucrose--SHR model in terms of hypertension and superiority of fructose--SDR model in terms of hyperinsulinemia, hypertriglyceridemia, and hypercholesterolemia. Both models showed similar postintervention degree of glucose tolerance. CONCLUSIONS: The fructose-fed SDR model represents a predominantly environmentally acquired MS, whereas the SHR model is less affected by dietary intervention and better displays the predominantly genetic spontaneous appearance of the syndrome. This fundamental difference should be taken into consideration when choosing an animal model to study the MS.


Subject(s)
Dietary Carbohydrates/administration & dosage , Disease Models, Animal , Fructose/administration & dosage , Metabolic Syndrome , Animals , Metabolic Syndrome/etiology , Metabolic Syndrome/genetics , Rats , Rats, Inbred SHR , Rats, Sprague-Dawley , Sucrose/administration & dosage
15.
Hypertens Res ; 31(1): 135-40, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18360028

ABSTRACT

The metabolic syndrome (MS) is a common risk factor for cardiovascular disease and type-2 diabetes. Recently, telmisartan, an angiotensin II receptor antagonist that has an antihypertensive effect, has been reported to be a partial peroxisome proliferator-activated receptor gamma (PPARgamma) agonist. The anti-diabetic hormone adiponectin has been recognized as a marker of in vivo PPARgamma activation. Therefore, we studied telmisartan's effect on the metabolic profile and adiponectin levels in a fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rat model. Twenty-four male Sprague-Dawley rats were divided into three groups (eight in each). One group of control rats was fed standard chow for 5 weeks while a second was fed a fructose-enriched diet. A third group was fed a fructose-enriched diet for 5 weeks and treated with telmisartan 5 mg/kg/day during the last 2 weeks. Fructose feeding increased systolic blood pressure (mean+/-SEM), from 130+/-1 to 148+/-2 mmHg, insulin from 0.26+/-0.03 to 0.68+/-0.08 ng/mL, and triglycerides from 102+/-6 to 285+/-23 mg/dL (p<0.05 for all variables). Telmisartan treatment reversed these effects and reduced blood pressure to 125+/-2 mmHg, insulin levels to 0.41+/-0.07 ng/mL, and triglycerides to 146+/-18 mg/dL (p<0.05 for all variables), while attenuating the increase in body weight during weeks 3 to 5. In contrast, telmisartan did not affect plasma adiponectin levels. In conclusion, although telmisartan is considered a partial PPARgamma agonist, its beneficial effect in the fructose-induced hypertension, hypertriglyceridemia, and hyperinsulinemia rat model is apparently not mediated by adiponectin elevation but rather by direct inhibition of AT1 receptor.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/pharmacology , Benzimidazoles/pharmacology , Benzoates/pharmacology , Fructose , Hyperinsulinism/chemically induced , Hyperinsulinism/metabolism , Hyperlipidemias/chemically induced , Hyperlipidemias/metabolism , Hypertension/chemically induced , Hypertension/metabolism , Adiponectin/biosynthesis , Animals , Diet , Insulin/blood , Male , Metabolic Syndrome/chemically induced , Metabolic Syndrome/metabolism , Rats , Rats, Sprague-Dawley , Telmisartan , Triglycerides/blood
16.
Am J Hypertens ; 21(3): 348-51, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18219301

ABSTRACT

BACKGROUND: Melatonin, the primary hormone of the pineal gland, is a known modulator of various physiological processes. The aim of this study was to evaluate the role of melatonin in the pathogenesis of hypertension in rats with metabolic syndrome and to assess whether melatonin supplementation prevents the development of hypertension in this model. METHODS: Twenty male Sprague-Dawley (SD) rats were fed either a high fructose diet (n = 10) or a regular diet (control; n = 10) for 5 weeks. Urinary excretion of 6-hydroxymelatoninsulfate (a metabolite of melatonin) was measured at the beginning and the end of the study. An additional 20 SD rats were fed with the same diets but with a supplementation of melatonin (30 mg/kg/day) in their drinking water. Blood pressure (BP) was measured every week. RESULTS: BP increased significantly in rats fed with a high fructose diet and remained unchanged in the control group. The BP rise was associated with a significant decrease in melatonin secretion during sleep. Melatonin supplementation prevented the BP rise in fructose fed rats. BP increased by 14.6 +/- 1.0 mm Hg in the fructose fed rats, whereas it increased by only 3 +/- 2.6 mm Hg in rats fed with fructose and melatonin (P < 0.001 between groups). CONCLUSIONS: Melatonin secretion decreased in fructose fed rats that developed hypertension. Administration of melatonin blunted this BP rise. These data suggested that melatonin plays a role in the pathogenesis of hypertension in rats with metabolic syndrome.


Subject(s)
Hypertension/etiology , Hypertension/physiopathology , Melatonin/physiology , Metabolic Syndrome/physiopathology , Animals , Blood Pressure/drug effects , Body Weight/drug effects , Dietary Sucrose/pharmacology , Dietary Supplements , Disease Models, Animal , Fructose/administration & dosage , Fructose/pharmacology , Hypertension/prevention & control , Male , Melatonin/pharmacology , Melatonin/urine , Rats , Rats, Sprague-Dawley , Triglycerides/blood
17.
Harefuah ; 146(1): 18-21, 79, 2007 Jan.
Article in Hebrew | MEDLINE | ID: mdl-17294842

ABSTRACT

This study aimed to evaluate the frequency of attenuated decline in nocturnal blood pressure (BP) in diabetic hypertensive patients, and characterize those who don't decrease BP during nighttime. A total of 61 hypertensive patients (26 males and 35 females, mean age 65.8+/-10) were included in the study. Patients were defined as hypertensive if their daytime pressure exceeded 140/90 (the definition relevant at the time of our study) or if they were on antihypertensive treatment. All patients underwent 24 hour Ambulatory BP Monitoring (ABPM) using Suntech Accutracker Dx. Subjects with nocturnal fall in SBP, DBP or MAP of less than 10% of daytime values were classified as non-dippers. Echocardiography and renal function were also evaluated. Two thirds of the subjects were non-dippers. The percentage of dippers among women was higher than that observed in men: SBP 34% versus 19% and DBP 48% versus 38% (the difference is statistically significant with p< 0.01). Non-significant correlation was observed between absence of nocturnal decline, age and gender. The 24 hour ABPM measurements should be recommended in all diabetic hypertensive patients in whom aggressive treatment covering nighttime should be offered.


Subject(s)
Blood Pressure Monitoring, Ambulatory , Diabetic Angiopathies/physiopathology , Hypertension/physiopathology , Aged , Circadian Rhythm , Female , Humans , Male , Middle Aged
18.
Am J Hypertens ; 20(2): 206-10, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17261469

ABSTRACT

BACKGROUND: The health hazard of the metabolic syndrome (MS) is increasing, yet there is no effective pharmacologic treatment to this entity as a whole. Recently, hypoadiponectinemia was found to play an important role in the development of MS. We studied the effect of the PPAR-gamma agonist rosiglitazone on adiponectin and the metabolic profile in the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat model. METHODS: Thirty male Sprague-Dawley rats were divided into three groups. Ten were fed standard rat chow for 5 weeks, 10, a fructose-enriched diet for 5 weeks, and 10, a fructose-enriched diet for 5 weeks, with rosiglitazone 10 mg/kg/d added during the last 2 weeks. Blood pressure (BP), oral glucose tolerance test (OGTT), plasma insulin, triglycerides, and adiponectin were recorded, as well as mRNA levels of the adiponectin gene in visceral adipose tissue. RESULTS: Fructose-fed rats developed MS as manifested by the increase in systolic BP (from 139 +/- 3 to 158 +/- 4 mm Hg, P < .05), insulin (from 26 +/- 1.6 to 40 +/- 2.5 muU/mL, P < .05), triglycerides (from 91 +/- 9 to 304 +/- 24 mg/dL, P < .05), and impaired OGTT (area under the curve from 13,894 +/- 246 to 17,725 +/- 700 mg/dL/min). Treatment with rosiglitazone reversed these effects and reduced BP to 133 +/- 7 mm Hg, insulin levels to 30 +/- 2.8 muU/mL, triglycerides to 116 +/- 9 mg/dL, and the OGTT to 15,415 +/- 372 mg/dL/min (P < .05 for all variables). In addition, rosiglitazone increased plasma levels of adiponectin fourfold from 4.3 +/- 0.1 to 18.4 +/- 0.6 mug/mL (P < .05). This increase was coupled with 3.8-fold increase in adiponectin mRNA in visceral adipose tissue. CONCLUSIONS: This study shows for the first time that in an animal model of MS, the insulin sensitizer, rosiglitazone, improves the metabolic profile and increases plasma levels of adiponectin and its gene expression. It is possible therefore that rosiglitazone exerts its beneficial effects by increasing the levels of adiponectin.


Subject(s)
Adiponectin/blood , Hypoglycemic Agents/therapeutic use , Metabolic Syndrome/drug therapy , PPAR gamma/agonists , Thiazolidinediones/therapeutic use , Adiponectin/genetics , Adiponectin/metabolism , Adipose Tissue/chemistry , Animals , Blood Pressure/drug effects , Diet , Disease Models, Animal , Fructose/administration & dosage , Glucose Tolerance Test , Hypoglycemic Agents/pharmacology , Insulin/blood , Male , Metabolic Syndrome/chemically induced , RNA, Messenger/analysis , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Rosiglitazone , Thiazolidinediones/pharmacology , Triglycerides/blood , Up-Regulation
19.
Am J Med ; 119(10): 898-902, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17000226

ABSTRACT

PURPOSE: Nocturnal hypertension is associated with a high risk of morbidity and mortality. A blunted nocturnal surge in melatonin excretion has been described in nondipping hypertensive patients. We therefore studied the potency of melatonin to reduce nighttime blood pressure (BP) in treated hypertensive patients with nocturnal hypertension. PATIENTS AND METHODS: Thirty-eight treated hypertensive patients (22 males, mean age 64+/-11 years) with confirmed nocturnal hypertension (mean nighttime systolic BP >125 mm Hg), according to repeated 24-hour ambulatory blood pressure monitoring (ABPM), were randomized in a double-blind fashion to receive either controlled release (CR)-melatonin 2 mg or placebo 2 hours before bedtime for 4 weeks. A 24-hour ABPM was then performed. RESULTS: Melatonin treatment reduced nocturnal systolic BP significantly from 136+/-9 to 130+/-10 mm Hg (P=.011), and diastolic BP from 72+/-11 to 69+/-9 mm Hg (P=.002), whereas placebo had no effect on nocturnal BP. The reduction in nocturnal systolic BP was significantly greater with melatonin than with placebo (P=.01), and was most prominent between 2:00 AM and 5:00 AM (P=.002). CONCLUSIONS: Evening CR-melatonin 2 mg treatment for 4 weeks significantly reduced nocturnal systolic BP in patients with nocturnal hypertension. Thus, an addition of melatonin 2 mg at night to stable antihypertensive treatment may improve nocturnal BP control in treated patients with nocturnal hypertension.


Subject(s)
Antihypertensive Agents/administration & dosage , Circadian Rhythm , Hypertension/drug therapy , Hypertension/physiopathology , Melatonin/administration & dosage , Adult , Aged , Aged, 80 and over , Delayed-Action Preparations , Double-Blind Method , Female , Humans , Male , Middle Aged , Treatment Outcome
20.
Am J Hypertens ; 18(10): 1306-12, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16202853

ABSTRACT

BACKGROUND: Pheochromocytoma, a rare and usually curable cause of hypertension, is characterized by symptoms and signs related to increased catecholamine secretion. Pregnancy can elicit clinical manifestations of otherwise unrecognized pheochromocytoma. METHODS AND RESULTS: Four women, ranging in age from 27 to 37 years, were referred to the hypertension clinic with the following presentations: 1) a 35-year-old woman, diagnosed with gestational hypertension and headaches during the third trimester of her pregnancy and 5 months after delivery, was hospitalized with pulmonary edema. Echocardiography revealed severe dilated left ventricular (LV) dysfunction. Cardiac function was normalized after surgical resection of a pheochromocytoma from her left adrenal; 2) a 37-year-old woman suffered from preeclampsia, persistent hypertension and orthostatic hypotension after a cesarean section. A diagnostic work-up revealed a catecholamine-secreting paraganglioma in the retroperitoneum. The patient underwent a laparosopic resection of the tumor; 3) a 27-year-old woman suffered from hypertension and episodes of palpitations, sweating, and dyspnea in the first trimester of her pregnancy. An ultrasound revealed a 5-cm mass in the left adrenal. She underwent a left adrenalectomy at the 17th week of pregnancy, which confirmed the diagnosis of pheochromocytoma; 4) a 34-year-old woman, at the 26th week of pregnancy, presented with an acute loss of vision and blood pressure of 230/140 mm Hg. Fundoscopy showed papilledema with soft exudates in both eyes. Chemical studies were positive and imaging revealed a left adrenal pheochromocytoma. Despite aggressive medical treatment, fetal distress mandated a laparotomy at the end of the 28th week of pregnancy. A healthy newborn was delivered and resection of the adrenal tumor confirmed the diagnosis of pheochromocytoma. CONCLUSIONS: Although rare, pheochromocytoma can cause severe peripartum hypertension. Screening for pheochromocytoma, ideally with plasma-free metanephrines, should be considered in cases of peripartum hypertension.


Subject(s)
Adrenal Gland Neoplasms/complications , Hypertension, Pregnancy-Induced/etiology , Pheochromocytoma/complications , Retroperitoneal Neoplasms/complications , Adrenal Gland Neoplasms/diagnosis , Adrenal Gland Neoplasms/surgery , Adult , Echocardiography , Female , Humans , Hypertension, Pregnancy-Induced/diagnosis , Laparotomy , Magnetic Resonance Imaging , Pheochromocytoma/diagnosis , Pheochromocytoma/surgery , Pregnancy , Pregnancy Complications, Cardiovascular/diagnosis , Pregnancy Complications, Cardiovascular/etiology , Pregnancy Complications, Neoplastic/diagnosis , Pregnancy Complications, Neoplastic/etiology , Retroperitoneal Neoplasms/diagnosis , Retroperitoneal Neoplasms/surgery , Tomography, X-Ray Computed , Ventricular Dysfunction, Left/diagnosis , Ventricular Dysfunction, Left/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...